B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19th century, but only the discovery of aquaporin-4 autoantibodies in a major subset of affected patients in 2004 led to a fundamentally revised disease concept: Neuromyelits optica spectrum disorders (...
Main Authors: | Jan Traub, Leila Husseini, Martin S. Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/1/37 |
Similar Items
-
Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials
by: Fanxin Kong, et al.
Published: (2021-07-01) -
CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
by: Chihiro Namatame, et al.
Published: (2021-01-01) -
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
by: Cimbora, D., et al.
Published: (2022) -
Neuromyelitis optica spectrum disorders in pediatric patients
by: Yu. V. Tokareva, et al.
Published: (2018-04-01) -
Late Onset of Neuromyelitis Optica Spectrum Disorders
by: Yara Dadalti Fragoso, et al.
Published: (2019-07-01)